1. Efficacy of intralesional pentoxifylline versus intralesional steroid versus intralesional vitamin D in treatment of keloid.
- Author
-
Galal SA, El-Barbary RA, and Madkour DKAEW
- Subjects
- Humans, Adult, Male, Female, Treatment Outcome, Middle Aged, Adolescent, Young Adult, Pentoxifylline administration & dosage, Pentoxifylline therapeutic use, Keloid drug therapy, Injections, Intralesional, Triamcinolone Acetonide administration & dosage, Triamcinolone Acetonide therapeutic use, Vitamin D administration & dosage, Vitamin D analogs & derivatives
- Abstract
Several treatment modalities have been used for the treatment of keloid scarring but the optimal treatment has not yet been identified. Corticosteroids reduce excessive scarring by reducing collagen synthesis. Vitamin D can curb inflammation by inhibiting the activation and migration of leukocytes. Pentoxifylline is a methyl xanthine derivative initially developed for its vasodilatory properties. Evaluation and comparison between three modalities of treatment for keloid; intralesional vitamin D, pentoxifylline, and steroid. Forty-five patients with keloid lesions were divided into 3 groups; The first group: 15 patients were treated with intralesional triamcinolone acetonide. The second group: 15 patients treated with intralesional pentoxifylline. The third group: 15 patients treated with intralesional vitamin D. The response was evaluated clinically, Vancouver scar scale and patient satisfaction scale. At the end of the study, all groups showed highly statistically significant improvement compared to the baseline. The first group which was treated with triamcinolone acetonide showed excellent and good improvement 53% and 47% respectively. The second group which was treated with pentoxifylline showed excellent and good improvement 6.7% and 73.3% respectively. The third group which was treated with vitamin D showed excellent and good 6.7% and 86.7% respectively. Intralesional vitamin D and pentoxifylline are safe and effective therapeutic options for keloid lesions., Competing Interests: Declarations. Ethical approval: Ethical consideration: this study was obtained from the Research ethics committee of the Faculty of Medicine for Girls, Cairo, Al-Azhar University (FMG-IRB) met at the Faculty of Medicine for Girls, Nasr City with IRB 1318.The manuscript is an original unpublished work, and it is not submitted for publication elsewhere. Competing interests: The authors declare no competing interests., (© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2025
- Full Text
- View/download PDF